License Amendment Approval for Strontium-82 For Manhattan Isotope Technology By Positron Corporation

The major molecular imaging healthcare company, Positron Corporation (OTCBB:POSC), specializing in the field of  nuclear cardiology, informed that, The Manhattan Isotope Technology (MIT) has been granted approval of its radioactive materials license amendment.

Facilitated by the Texas Department of State Health Services- Radiation Control Program, the recent amendment will now enable the processing of solutions, containing Sr-82 and multiple other radioisotopes on a broader scale.

 According to The Chief Technical Officer, Jason Kitten, "Positron and MIT are rapidly implementing a new foundation for cardiac PET by increasing the supply and reliability of Sr-82. Positron has designed a superior integrated business model for the reliability and expansion of cardiac PET in the US. With this latest license approval, MIT has significantly accelerated Positron's Sr-82 mission and will begin supporting Sr-82 supply in 2012, further strengthening Positrons goal of solidifying cardiac PET's progression in the US."

 Read more at http://www.positron.com/?p=770

 SOURCE Positron Corporation